Plasma cell leukemia: update on biology and therapy

References

• Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer. 2009;115:5734–5739.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754–759.
   PubMed Web of Science ®Google Scholar
• Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–3734.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133:813–818.
   PubMed Web of Science ®Google Scholar
• Mohite S, Baladandayuthapani V, Thomas SK, et al. Circulating plasma cells by routine complete blood count identify patients with similar outcome as plasma cell leukemia. Blood. 2013;122:5356.
   Web of Science ®Google Scholar
• An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94:257–264.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Musto P, Simeon V, Todoerti K, et al. Primary plasma cell leukemia: identity card 2016. Curr Treat Options Oncol. 2016;17:19.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kryukov F, Rihova L, et al. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015;95:16–26.
   PubMed Web of Science ®Google Scholar
• Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011;25:107–112.
   PubMed Web of Science ®Google Scholar
• Fernández de Larrea C, Kyle RA, Durie BGM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–791.
   PubMed Web of Science ®Google Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–1052.
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032–1037.
   PubMed Web of Science ®Google Scholar
• Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–1272.
   PubMed Web of Science ®Google Scholar
• Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–1068.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907–912.
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pochintesta L, Cocito F, et al. Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. Br J Haematol. 2013;162:555–558.
   PubMed Web of Science ®Google Scholar
• Kraj M, Kopeć-Szlęzak J, Pogłód R, et al. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011;35:169–176.
   PubMed Web of Science ®Google Scholar
• Vande Broek I, Van de Broek I, Leleu X, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica. 2006;91:200–206.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Lokhorst HM, Anderson KC, et al. How I treat plasma cell leukemia. Blood. 2012;120:2376–2389.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barillé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977–1982.
   PubMed Web of Science ®Google Scholar
• Guo J, Su J, He Q, et al. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Hematology. 2016;21:152–161.
   PubMed Web of Science ®Google Scholar
• Murray ME, Gavile CM, Nair JR, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014;123:3770–3779.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Roussel M, Campion L, et al. Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia. 2012;26:158–159.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématolo. Blood. 2001;97:822–825.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48:624–636.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Yeung J, et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res. 2009;33:259–262.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Price-Troska T, Gonzalez-Paz N, et al. Clinical significance of TP53 mutation in myeloma. Leukemia. 2007;21:582–584.
   PubMed Web of Science ®Google Scholar
• Eymin B, Gazzeri S, Brambilla C, et al. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene. 2002;21:2750–2761.
   PubMed Web of Science ®Google Scholar
• Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–5014.
   PubMed Web of Science ®Google Scholar
• Simeon V, Todoerti K, La Rocca F, et al. Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine. Int J Mol Sci. 2015;16:17514–17534.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with total therapy protocols. Leukemia. 2012;26:2398–2405.
   PubMed Web of Science ®Google Scholar
• Mosca L, Musto P, Todoerti K, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol. 2013;88:16–23.
   PubMed Web of Science ®Google Scholar
• Todoerti K, Agnelli L, Fabris S, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19:3247–3258.
   PubMed Web of Science ®Google Scholar
• Lionetti M, Musto P, Di Martino MT, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013;19:3130–3142.
   PubMed Web of Science ®Google Scholar
• Cifola I, Lionetti M, Pinatel E, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6:17543–17558.
   PubMed Web of Science ®Google Scholar
• Egan JB, Shi C-X, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012;120:1060–1066.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–1076.
   PubMed Web of Science ®Google Scholar
• Costello R, Sainty D, Bouabdallah R, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res. 2001;25:103–107.
   PubMed Web of Science ®Google Scholar
• Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukemia: a report on 15 patients. Eur J Haematol Suppl. 1989;51:76–83.
   PubMedGoogle Scholar
• Jiménez-Zepeda VH, Domínguez VJ. Plasma cell leukemia: a rare condition. Ann Hematol. 2006;85:263–267.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Martini V, Levi A, et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma. 2007;48:180–182.
   PubMed Web of Science ®Google Scholar
• Johnston RE, Abdalla SH. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma. 2002;43:351–354.
   PubMed Web of Science ®Google Scholar
• Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol. 2002;117:996–997.
   PubMed Web of Science ®Google Scholar
• Benson DM, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48:1423–1425.
   PubMed Web of Science ®Google Scholar
• Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res. 2008;32:1637–1638.
   Google Scholar
• Guglielmelli T, Merlini R, Giugliano E, et al. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol. 2009;2009:867380.
   PubMedGoogle Scholar
• Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28:222–225.
   PubMed Web of Science ®Google Scholar
• Gay F, Mina R, Troia R, et al. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin Drug Metab Toxicol. 2013;9:1517–1527.
   PubMed Web of Science ®Google Scholar
• Mele G, Coppi MR, Guaragna G, et al. Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia. Leuk Res. 2016;40:30–32.
   PubMed Web of Science ®Google Scholar
• Willenbacher E, Willenbacher W, Gastl G, et al. In-vitro actvity of pixantrone (PIX) in plasma cell leukaemia (PCL) and early clinical activity in a Pixantrone–Pomalidomide–Dexamethasone (PiPoD) combination. Blood. 2014;124:5732–5732.
   Web of Science ®Google Scholar
• Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007;109:2285–2290.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23:1499–1502.
   PubMed Web of Science ®Google Scholar
• Katodritou E, Terpos E, Kelaidi C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014;89:145–150.
   PubMed Web of Science ®Google Scholar
• Reece DE, Phillips M, Chen CI, et al. Induction therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for primary plasma cell leukemia (pPCL). Blood. 2013;122:abstract 5378.
   PubMed Web of Science ®Google Scholar
• Royer B, Minvielle S, Diouf M, et al. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the intergroupe francophone du myélome. J Clin Oncol. 2016;34:2125–2132.
   PubMed Web of Science ®Google Scholar
• Cavo M, Pantani L, Pezzi A, et al. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia. 2015;29:2429–2431.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Weller E, Lonial S, et al. Lenalidomide, Bortezomib, and Dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679–686.
   PubMed Web of Science ®Google Scholar
• Jimenez-Zepeda VH, Reece DE, Trudel S, et al. Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma. 2015;56:232–235.
   PubMed Web of Science ®Google Scholar
• McElwain TJPR. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;2:822–824.
   PubMed Web of Science ®Google Scholar
• Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95:804–809.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26:1091–1097.
   PubMed Web of Science ®Google Scholar
• Morris C, Iacobelli S, Gahrton G, et al. Has allogeneic transplantation a role in the management of plasma cell leukaemia? a study on behalf of the myeloma subcomittee of the chronic leukaemia working party of the EBMT. Blood. 2011;118:Abstract 2008.
   Web of Science ®Google Scholar
• Lebovic D, Zhang L, Alsina M, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011;11:507–511.
   Google Scholar
• Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy. 2005;25:1820–1825.
   PubMed Web of Science ®Google Scholar